Evidence map›Paper›PMID 16515684›Full record

ArticleBMC pharmacology2006

Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.

Dawn D Han, Howard H Gu

Open access · hybridAbstract readComparative Study
In one paragraph

Article in BMC pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 217 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
217citing papers in PubMed, 8 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

217 citing papers in PubMed, 8 syntheses or guidelines pooled it, 418 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Effects of MDMA and Intranasal oxytocin on social and emotional processing.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011
    Trial
  19. Atomoxetine attenuates dextroamphetamine effects in humans.The American journal of drug and alcohol abuse · 2009
    Trial
  20. Disulfiram enhances subjective effects of dextroamphetamine in humans.Pharmacology, biochemistry, and behavior · 2008
    Trial

157 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Dawn D HanDepartment of Pharmacology, The Ohio State University College of Medicine, USA. han.195@osu.edu
Howard H Gu
The Ohio State University · US

Funding

Mechanism of drug addictionR01DA014610 · NIDA · YALE UNIVERSITY · PI GU, HOWARD H · 2002 to 2013
$3.1M
NIDA NIH HHS DA014610NIDA NIH HHS R01 DA014610
6 · The paper itself

Abstract

backgroundThe plasma membrane neurotransmitter transporters terminate neurotransmissions by the reuptake of the released neurotransmitters. The transporters for the monoamines dopamine, norepinephrine, and serotonin (DAT, NET, and SERT) are targets for several popular psychostimulant drugs of abuse. The potencies of the psychostimulant on the monoamine transporters have been studied by several laboratories. However, there are significant discrepancies in the reported data with differences up to 60-fold. In addition, the drug potencies of the 3 monoamine transporters from mouse have not been compared in the same experiments or along side the human transporters. Further studies and systematic comparisons are needed.

resultsIn this study, we compared the potencies of five psychostimulant drugs to inhibit human and mouse DAT, SERT and NET in the same cellular background. The KI values of cocaine to inhibit the 3 transporters are within a narrow range of 0.2 to 0.7 microM. In comparison, methylphenidate inhibited DAT and NET at around 0.1 microM, while it inhibited SERT at around 100 microM. The order of amphetamine potencies was NET (KI = 0.07-0.1 microM), DAT (KI approximately 0.6 microM), and SERT (KI between 20 to 40 microM). The results for methamphetamine were similar to those for amphetamine. In contrast, another amphetamine derivative, MDMA (3-4 methylenedioxymethamphetamine), exhibited higher potency at SERT than at DAT. The human and mouse transporters were similar in their sensitivities to each of the tested drugs (KI values are within 4-fold).

conclusionThe current and previous studies support the following conclusions: 1) cocaine blocks all 3 monoamine transporters at similar concentrations; 2) methylphenidate inhibits DAT and NET well but a 1000-fold higher concentration of the drug is required to inhibit SERT; 3) Amphetamine and methamphetamine are most potent at NET, while being 5- to 9-fold less potent at DAT, and 200- to 500-fold less potent at SERT; 4) MDMA has moderately higher apparent affinity for SERT and NET than for DAT. The relative potencies of a drug to inhibit DAT, NET and SERT suggest which neurotransmitter systems are disrupted the most by each of these stimulants and thus the likely primary mechanism of drug action.

Indexed as

Serotonin Plasma Membrane Transport ProteinsAnimalsCell LineDopamine Plasma Membrane Transport ProteinsDose-Response Relationship, DrugHaplorhiniHumansMiceNorepinephrine Plasma Membrane Transport ProteinsPsychotropic DrugsSpecies SpecificityDopamine Plasma Membrane Transport ProteinsNorepinephrine Plasma Membrane Transport ProteinsPsychotropic DrugsSerotonin Plasma Membrane Transport Proteins

Identifiers

PMID16515684
PMCPMC1448202
OpenAlexW1788048136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.